Lung cancer is one of the most common, and deadly, forms of cancer. Alone, it is responsible for more deaths than breast, colorectal and prostate cancer combined. It remains a significant challenge, both in the clinical and research settings.
The key to combating cancer lies in understanding the ways it operates. Like for all cancers, early diagnosis presents the best chances of survival. Unfortunately, lung cancer often remains undiagnosed until it's too late.
For this reason, a critical component of our strategy against lung cancer is exploring how
Moreover, at the root of our significant advancements is a focus on understanding the genetics and disease pathways behind cancer. Genomic testing and advanced diagnostics can identify mutations in patients to predict the best therapy for the best possible outcomes, ultimately giving physicians and other healthcare professionals the ability to deliver truly
© 2023, Roche Products (New Zealand) Ltd, Auckland. This site is intended for New Zealand audiences. Please be aware that we do not take any responsibility for accessing such information which may not comply with any legal process, regulation, registration or use in the country of your origin. Access to this site is subject to the terms in our Legal and Privacy Statement. You accept these terms by continuing to access this site.
M-NZ-00000625-v6.0/MR9618/NOV23. This site was last updated NOV2023